Glioblastoma (GBM) is one of the most lethal human cancers. Genomic analyses are defining
the molecular architecture of GBM, uncovering relevant subsets of patients whose disease …

The genetic, functional or compositional heterogeneity of healthy and diseased tissues
presents major challenges in drug discovery and development. Such heterogeneity hinders the …

As tumours evolve, the daughter cells of the initiating cell often become molecularly
heterogeneous and develop different functional properties and therapeutic vulnerabilities. In …

Background The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
or mutated in glioblastomas, but only 10 to 20 percent of patients have a response to …

Cancer immunoresistance and immune escape 1 , 2 , 3 may play important roles in tumor
progression and pose obstacles for immunotherapy. Expression of the immunosuppressive …

Comprehensive knowledge of the genomic alterations that underlie cancer is a critical
foundation for diagnostics, prognostics, and targeted therapeutics. Systematic efforts to analyze …

Systematic efforts are underway to decipher the genetic changes associated with tumor
initiation and progression 1 , 2 . However, widespread clinical application of this information is …

Background There is much discussion in the cancer drug development community about
how to incorporate molecular tools into early-stage clinical trials to assess target modulation, …

… PS Mischel was also supported by NS43147 and a grant from Accelerate Brain Cancer Cure.
WA Freije is a scholar of the Women’s Reproductive Health Research Center (Grant No. 5-…

Glioblastoma is the most common primary malignant brain tumor of adults and one of the
most lethal of all cancers. Patients with this disease have a median survival of 15 months from …